News | News By Subject | News by Disease News By Date | Search News

Leukemia [Chronic myelogenous leukemia (CML)] News Articles

Get Our FREE
Industry eNewsletter
Top Breaking News
AmerisourceBergen Corporation (ABC) the “Pony to Ride” for Biosimilar Opportunities, Says UBS     3/16/2015
Analyst: Current Crop of Biotech IPOs a Mixed Bag of Low Market Caps, Little Data     12/3/2014
Best Value In Biotech? Actavis (ACT), Says UBS     11/17/2014
Novartis AG (NVS): New Five-Year Data Support Superiority Of Tasigna Over Glivec     12/9/2013
Genentech (RHHBY)'s Gazyva Extends Leukemia Patients’ Survival     11/7/2013
Bristol-Myers Squibb Company (BMY) Gets FDA Approval for New Labeling for Sprycel     6/21/2013
Ariad Pharmaceuticals, Inc. (ARIA) Wins FDA Approval for Drug to Treat Rare Leukemias     12/18/2012
FDA Approves Teva Pharmaceutical Industries Limited (TEVA) Leukemia Drug     10/30/2012
Ariad Pharmaceuticals, Inc. (ARIA)'s Ponatinib Shown to Aid in Leukemia When Other Drugs Fail     6/4/2012
National Institute for Clinical Excellence (NICE) Backs Novartis AG (NVS)'s Tasigna for CML, Rejects Bristol-Myers Squibb Company (BMY)'s Sprycel     1/16/2012
Bristol-Myers Squibb Company (BMY)'s Sprycel Wins European Market Approval for Chronic Myeloid Leukemia     12/10/2010
FDA Grants Full Approval for Bristol-Myers Squibb Company (BMY)'s SPRYCEL(R) (dasatinib) for the Treatment of Adults with Chronic Myeloid Leukemia Who Are Resistant or Intolerant to Prior Therapies Including Gleevec(R)     5/27/2009
EpiCept Corporation (EPCT)'s Ceplene(R) Receives Positive European Opinion for Approval     7/25/2008
GlaxoSmithKline (GSK) Signs Record $2.1 Billion Deal For Genmab A/S (GNMSF.PK) Drug     12/19/2006
Genta Incorporated (GNTA) Release: Briefing Documents Posted For FDA Committee Review Of Genasense(R) New Drug Application     9/5/2006

News from Around the Web
While Amgen (AMGN)-Size Biotechs Run Into Trouble, These Are The Biotechs With The Most Promising Pipelines     6/19/2017
New Drug Stops Aggressive Form of Childhood Leukemia, Weill Cornell Medical College and University of California, San Francisco (UCSF) Study     5/25/2011
Imatinib Normalizes Life Expectancy in CML, University of Milano Bicocca Study     3/28/2011
American Society of Hematology: New CML Drug Still Beating Out Its Predecessor, Royal Adelaide Hospital Study     12/8/2010
American Society of Hematology: Benefits Last for Nilotinib in CML, University of Bologna Study     12/7/2010
Leukaemia Drug Boost for Patients, Victor Segalen Bordeaux University Study     10/20/2010
Discovery Suggests Possible Treatment Strategy for Aggressive Leukemias, Duke University Medical Center Study     7/19/2010
Protein That Predicts Prognosis Of Leukemia Patients May Also Be A Therapeutic Target, Whitehead Institute and Children's Hospital Boston Reveals     7/12/2010
Cancer Drug Gleevec Linked to Muscle Damage, Data Published in New England Journal of Medicine     6/19/2008
Data Confirm Dasatinib's Effectiveness in Resistant Chronic Myelogenous Leukemia, Dana-Farber Cancer Institute Study     12/14/2007
M. D. Anderson Cancer Center: Early Phase II Results Show Bosutinib Safe, Effective for CML     12/12/2007
Oregon Health & Science University (OHSU) Cancer Institute Research Discovery Opens New Window To Understanding Chronic Myeloid Leukemia     12/11/2007
Dasatinib, Nilotinib Show Strong Early Results as Frontline Therapy for Chronic Myelogenous Leukemia, M. D. Anderson Cancer Center Study     12/10/2007
Leukemia Drug Turns Mini-Molecules Up, Cancer Genes Down     3/1/2007
Mouse Mimics Chronic Leukemia, Will Aid Drug Development     8/23/2006

Press Releases
Avillion And Pfizer (PFE) Release: FDA And EMA Accept Regulatory Submissions For BOSULIF® (Bosutinib) For The Treatment Of Patients With Newly Diagnosed Ph+ Chronic Myeloid Leukemia     8/29/2017
Novartis AG (NVS) Data Shows Half Of Eligible Ph+ CML-CP Patients Remain In Treatment-Free Remission Nearly Two Years After Stopping Tasigna     6/23/2017
Immune Pharma Announces Initiation Of Enrollment In Clinical Trial With Ceplene/ Low-Dose IL-2 In Chronic Myelomonocytic Leukemia (CMML)     6/20/2017
Cincinnati Children's Hospital Medical Center Release: Scientists Find Possible Achilles Heel Of Treatment Resistant Cancers     3/21/2017
Kura Oncology Doses First Patient In Phase II Study Of Tipifarnib In Chronic Myelomonocytic Leukemia     1/17/2017
Pfizer (PFE) And Avillion Announce Positive Top-Line Results For Phase III BFORE Study Of BOSULIF For First-Line Treatment Of Philadelphia Chromosome Positive Chronic Myeloid Leukemia     12/5/2016
Teva (TEVA) Announces Launch Of Generic Gleevec Tablets In The United States     8/5/2016
Mylan (MYL) And BioCon (BIOCON.NS) Announce Regulatory Submission For Proposed Biosimilar Pegfilgrastim Accepted For Review By European Medicines Agency     7/21/2016
Ariad (ARIA) Announces Long-Term Safety And Efficacy Data Of Ponatinib From Phase II Pace Clinical Trial     6/13/2016
ASCO2016: Novartis Pharmaceuticals Corporation (NVS) Data Show More Than 50 Percent Of Eligible Ph+ CML Patients Maintain Treatment-Free Remission (TFR) After Stopping Tasigna     6/6/2016
Bristol-Myers Squibb (BMY) To Present New Data Across Multiple Blood Cancers At The 57th Annual Meeting & Exposition Of The American Society of Hematology     11/30/2015
Novartis Pharmaceutical Corporation (NVS) Highlights Clinical Advances At American Society of Hematology 2015, Underscoring Leadership In Hematology Research     11/30/2015
Bristol-Myers Squibb (BMY) Release: FDA Approves U.S. Product Labeling Update For Sprycel (Dasatinib) To Include Five-Year First-Line And Seven-Year Second-Line Efficacy And Safety Data In Chronic Myeloid Leukemia In Chronic Phase     8/13/2015
Asterias Biotherapeutics Reports Second Quarter Results     8/11/2015
Bio-Path Holdings, Inc. (BPTH) Reports Second Quarter 2015 Operational And Financial Results     8/11/2015